The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma

被引:31
作者
Hua, Wei [1 ]
Yao, Yu [1 ]
Chu, Yiwei [2 ]
Zhong, Ping [1 ]
Sheng, Xiaofang [3 ]
Xiao, Baoguo [4 ]
Wu, Jingsong [1 ]
Yang, Bojie [1 ]
Mao, Ying [1 ]
Zhou, Liangfu [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200040, Peoples R China
[2] Fudan Univ, Shanghai Med Sch, Dept Immunol, Shanghai 200032, Peoples R China
[3] Shanghai Gamma Knife Hosp, Dept Radiotherapy, Shanghai 200235, Peoples R China
[4] Fudan Univ, Inst Neurol, Huashan Hosp, Shanghai 200040, Peoples R China
关键词
Malignant gliomas; Stem-like cell-associated antigens; Dendritic cells; Immunotherapy; IDENTIFICATION; VACCINATION; EXPRESSION; TARGET; LINES;
D O I
10.1007/s11060-011-0572-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To explore the immunogenicity of glioma stem-like cell-associated antigens (SAAs) from sorted or unsorted glioma tumor stem-like cells (TSCs) as well as irradiated TSCs. Two primary human malignant glioma lines (SHG62, SHG66) and U87 cell line were primarily cultured in the serum-free medium (SFM) supplemented with EGF/bFGF. TSCs were identified by their self-renewal, multi-lineage differentiation and tumorigenic activity. To prepare SAAs in vitro, CD133+ TSCs were sorted either by magnetic cell sorting or with irradiation (6 Gy).The cytotoxicity induced by autogenous myeloid dendritic cell (DC)-mediated SAA-specific cytotoxic T lymphocytes (CTLs) was assessed by the Just Another Method test. SHG62, SHG66, and U87 cells contained TSCs. CD133+ SAAs-specific CTLs were significantly more cytotoxic than effector cells loaded with unsorted SAA (P < 0.05). Effector cells loaded with irradiated SAAs were more cyotoxic than those with regular SAAs (P < 0.01). SAAs from CD133+ TSCs and irradiated TSCs provide highly immunogenic antigens. TSCs might be a novel source of antigens for DC vaccination against malignant gliomas.
引用
收藏
页码:149 / 157
页数:9
相关论文
共 27 条
  • [1] Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
    Bao, Shideng
    Wu, Qiulian
    McLendon, Roger E.
    Hao, Yueling
    Shi, Qing
    Hjelmeland, Anita B.
    Dewhirst, Mark W.
    Bigner, Darell D.
    Rich, Jeremy N.
    [J]. NATURE, 2006, 444 (7120) : 756 - 760
  • [2] Chi DDJ, 1997, AM J PATHOL, V150, P2143
  • [3] Cho William C S, 2009, Expert Rev Mol Diagn, V9, P411, DOI 10.1586/erm.09.34
  • [4] In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab
    Combs, Stephanie E.
    Schulz-Ertner, Daniela
    Roth, Wilfried
    Herold-Mende, Christel
    Debus, Juergen
    Weber, Klaus-Josef
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (03): : 873 - 882
  • [5] Dai Jie, 2003, Cancer Immun, V3, P1
  • [6] Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients
    Di Tomaso, Tiziano
    Mazzoleni, Stefania
    Wang, Ena
    Sovena, Gloria
    Clavenna, Daniela
    Franzin, Alberto
    Mortini, Pietro
    Ferrone, Soldano
    Doglioni, Claudio
    Marincola, Francesco M.
    Galli, Rossella
    Parmiani, Giorgio
    Maccalli, Cristina
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (03) : 800 - 813
  • [7] Treatment of astrocytomas
    Gonzalez, J
    Gilbert, MR
    [J]. CURRENT OPINION IN NEUROLOGY, 2005, 18 (06) : 632 - 638
  • [8] Imaizumi T, 1999, INT J CANCER, V83, P760, DOI 10.1002/(SICI)1097-0215(19991210)83:6<760::AID-IJC11>3.0.CO
  • [9] 2-R
  • [10] Lumniczky K, 2002, CANCER GENE THER, V9, P44